For almost 50 yr the federal government has been committed to building and maintaining the capacity of the university-based biomedical research system. The system of peer-reviewed research grant funding to universities has produced the most successful health research enterprise in the world. The philosophy and vision of this enterprise was articulated by Vanevar Bush in his classic prescription for the federal role in science called Science: The Endless Frontier. In this document, he provided not only recommendations for structures but more importantly, a vision of the proper role of government in what was accepted as a noble and valued societal effort.
Over the past 15 yr we have come to expect an annual struggle for funds; we've become used to the arguments that pit limited resources against expanding opportunities and used to fights over how much the NIH budget should increase and how many grants will be funded. Today, we face the same issues but the context has changed. The political discourse that underlies our enterprise has undergone a transformation in Washington. Whether it represents a temporary aberration in a 50-yr experience or a real sea change, we cannot tell. The issues raised by this political transformation, however, are so fundamental, I felt I could not ignore them in addressing these clinical research societies.
Even though many individuals responsible for funding this system remain committed to it, we find ourselves in an environment where some of the most fundamental assumptions about federal research funding and of the very value of biomedical research are being questioned.
We The public seems mistrustful of scientific experts who argue and disagree and who change their minds about diet and therapy, about risks and dangers. While we know that the process of scientific discourse is necessary to progress, when presented to a public woefully illiterate about science, disagreement among "experts" results in surprise, disappointment, and some disillusionment.
Finally, there is an amazing social change in our culture in which expertise is equated with elitism and the idea of dispassionate professionalism has been tossed aside and replaced with the assumption that expertise means corrupt self-interest. This last point, I believe, underlies, in part, the term limits movement and the myth of political salvation through the citizen politician, a rejection of the dreaded and mistrusted "professional."
The second difficult issue confronting our community is doubt about the value of medical innovation. This has come from the correlation and, in many cases, the actual connections between innovations in medicine and rising costs-more about this in a few minutes. So it is with the biomedical research enterprise. It is an investment that the whole society benefits from, whose efficacy emerges from the aggregate and over a long, or at least unpredictable, time scale. It is providing for the public good in the most profound and basic way, and the health it seeks to assure is a prerequisite for the life, liberty, and pursuit of happiness which we expect our government to support.
So what can we do? In short, we must be engaged. We must be knowledgeable about the benefits of science and be able to describe them without hype or false hope. We must use our intellectual and institutional resources to participate in improving scientific literacy without sacrificing our core missions. We must try to mobilize those who should be allies into a true alliance. These allies include the entire health care delivery system, business, voluntary health organizations, and others concerned with the social welfare in our society. We need to return the agenda of discourse back to the very value of biomedical research. There is no definitive argument for a given level of public funding for biomedical research, no absolute number of grants or clinical trials or trainees. Ultimately, the extent to which we are supported will be a direct reflection of the value our culture places on the process, the promise, and the progress of science.
